Redmile Group, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001425738

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 44 positions · Total reported value $1.37B · Top-10 concentration 71.6% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 71.1% · 6 new · 25 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.0% · vs SPY -14.1% · Prev Value $1.49B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.5% · Latest Value $1.37B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Redmile Group, LLC disclosed 44 equity positions with a combined reported value of $1.37B. The filing implies a focused portfolio: its ten largest positions account for 71.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were NRIX ($187.33M), KRYS ($175.49M), SRRK ($146.60M). By sector, the heaviest allocations are Health Care 95.3%, Other 4.7%. Versus the prior quarter, allocation shifted toward Other (+4.7pp) and away from Health Care (-4.7pp).

Versus the prior quarter, Redmile Group, LLC opened 6 new positions, trimmed 25 and fully exited 1, a turnover rate of 71.1% of positions. The portfolio's overlap with the prior quarter was 84% of names.

The largest new positions opened in Q3 2026 were GRTX ($61.10M), ATOS ($19.94M), VNDA ($15.34M).

Of the 1 positions fully exited versus the prior quarter, the largest were ESTA ($7.63M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GRTX ELECTRA THERAPEUTICS INC · $61.10M
  • ATOS ATOSSA THERAPEUTICS INC · $19.94M
  • VNDA VANDA PHARMACEUTICALS INC · $15.34M
  • VRDN VIRIDIAN THERAPEUTICS INC · $11.44M
  • TLGYF TCGX ACQUISITION CORP · $3.75M
  • OCUL OCULAR THERAPEUTIX INC · $1.87M

Fully Exited (vs previous quarter)

  • ESTA ESTABLISHMENT LABS HLDGS INC · prev qtr: $7.63M

Insider Transactions (Form 4)

Latest Redmile Group, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-08-06 Buy Attovia Therapeutics, Inc. 400,000 $17.00 SEC filing
2026-08-06 Buy Attovia Therapeutics, Inc. 200,000 $17.00 SEC filing
2026-08-06 Conversion Attovia Therapeutics, Inc. 782,854 — SEC filing
2026-07-22 Tax payment Atara Biotherapeutics, Inc. 60 — SEC filing
2026-07-22 Opt exercise Atara Biotherapeutics, Inc. 195,211 — SEC filing
2026-04-20 J FATE THERAPEUTICS INC 8,977,624 — SEC filing

All insider transactions →

Fund Profile

Redmile Group, LLC, based in Larkspur, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 44 positions worth $1.37B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: LARKSPUR, CA, United States
  • SEC registration: 801-67747 (status: Approved), registered 2007-04-19
  • Regulatory AUM (Form ADV): $4.70B as of 2026-08-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 20 private funds, of which 10 hedge funds
  • Website: redmilegroup.com

Portfolio Structure

  • 44 positions · $1.37B reported value (Q3 2026)
  • Top 10 holdings = 71.6% of reported value
  • Largest position: NRIX (NURIX THERAPEUTICS INC) at 13.7%
  • Average position size: $31.05M

Sector Tilt

  • Health Care 95.3%
  • (classified holdings cover 95% of value)

Quarterly Activity

  • Q3 2026: 6 new, 7 added, 25 reduced, 1 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to biotech/therapeutics (NRIX, ANNX, NGNE, RGNX) while reducing positions in clinical-stage gene therapy (KRYS, SRRK, STOK, IMNM), suggesting a bullish view on near-term pipeline catalysts or undervaluation in select names. 2. Key moves: - Added: NRIX (+93.9% shares), ANNX (+20.3% shares), NGNE (+10.6% shares), RGNX (+15.6% shares). - Reduced: KRYS (-16.5% shares), SRRK (-29.6% shares), STOK (-1.9% shares), IMNM (-11.2% shares), ABSI (-1.0% shares). - New: GRTX (ELECTRA THERAPEUTICS INC). 3. Portfolio structure: Highly active, concentrated in Health Care (biotech/gene therapy), with high risk appetite (small-cap, clinical-stage names). 4. Per-holding one-liner: - NRIX: NURIX THERAPEUTICS (protein-targeting therapeutics). - KRYS: KRYSTAL BIOTECH (gene therapy for rare diseases). - SRRK: SCHOLAR ROCK (muscle-targeted biologics). - STOK: STOKE THERAPEUTICS (splicing modulation). - IMNM: IMMUNOME (cancer immunotherapy). - ABSI: ABSCI (antibody development). - GRTX: ELECTRA THERAPEUTICS (immune-focused biotech). - ANNX: ANNEXON (neurodegeneration therapies). - NGNE: NEUROGENE (gene therapy for neurological disorders). - RGNX: REGENXBIO (gene therapy platform). 5. Style summary: Aggressive biotech fund rotating into high-conviction pipeline names while trimming fading clinical-stage bets.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:39

Sector Allocation

Health Care 95.3%
Other 4.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 7.90M $187.33M 13.71%
13.71%
Add
2 527.68K $175.49M 12.84%
12.84%
Reduce
3 3.03M $146.60M 10.73%
10.73%
Reduce
4 3.87M $100.59M 7.36%
7.36%
Reduce
5 4.36M $93.85M 6.87%
6.87%
Reduce
6 6.67M $71.85M 5.26%
5.26%
Reduce
7 5.43M $61.10M 4.47%
4.47%
New
8 14.28M $60.40M 4.42%
4.42%
Add
9 1.56M $43.46M 3.18%
3.18%
Add
10 5.05M $38.02M 2.78%
2.78%
Add
11 5.09M $34.69M 2.54%
2.54%
Reduce
12 12.87M $30.51M 2.23%
2.23%
Hold
13 2.46M $26.90M 1.97%
1.97%
Add
14 1.06M $25.96M 1.90%
1.90%
Reduce
15 1.16M $19.94M 1.46%
1.46%
New
16 1.74M $19.32M 1.41%
1.41%
Reduce
17 3.03M $16.97M 1.24%
1.24%
Hold
18 769.35K $15.34M 1.12%
1.12%
New
19 381.32K $14.65M 1.07%
1.07%
Reduce
20 11.58M $14.13M 1.03%
1.03%
Add
21 1.94M $14.06M 1.03%
1.03%
Hold
22 491.65K $13.02M 0.95%
0.95%
Hold
23 833.16K $11.44M 0.84%
0.84%
New
24 189.54K $11.37M 0.83%
0.83%
Reduce
25 974.49K $11.18M 0.82%
0.82%
Reduce
26 321.77K $10.43M 0.76%
0.76%
Reduce
27 7.19M $9.99M 0.73%
0.73%
Reduce
28 1.55M $9.75M 0.71%
0.71%
Reduce
29 296.61K $9.50M 0.69%
0.69%
Reduce
30 386.79K $9.43M 0.69%
0.69%
Hold
31 374.51K $8.32M 0.61%
0.61%
Reduce
32 191.04K $7.10M 0.52%
0.52%
Reduce
33 84.13K $6.44M 0.47%
0.47%
Reduce
34 636.85K $5.41M 0.40%
0.40%
Add
35 42.90K $4.90M 0.36%
0.36%
Reduce
36 519.88K $4.73M 0.35%
0.35%
Reduce
37 373.42K $4.39M 0.32%
0.32%
Reduce
38 292.82K $3.94M 0.29%
0.29%
Reduce
39 299.86K $3.75M 0.28%
0.28%
New
40 1.15M $3.50M 0.26%
0.26%
Reduce
41 2.29M $1.99M 0.15%
0.15%
Reduce
42 243.95K $1.87M 0.14%
0.14%
New
43 523.87K $1.79M 0.13%
0.13%
Reduce
44 772.13K $833.90K 0.06%
0.06%
Hold

FAQ

What did Redmile Group, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Redmile Group, LLC reported 44 equity positions worth $1.37B in aggregate; its largest disclosed positions were NRIX ($187.33M), KRYS ($175.49M), SRRK ($146.60M).

How large is Redmile Group, LLC's portfolio?

Redmile Group, LLC reported $1.37B of long equity holdings across 44 positions as of 2026-Q3. Top-10 holdings account for 71.6% of reported value.

What is Redmile Group, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/redmile/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →